New combo therapy aims to control early lung cancer without surgery
NCT ID NCT07517640
First seen Apr 12, 2026 · Last updated May 05, 2026 · Updated 2 times
Summary
This study tests whether combining a targeted drug (furmonertinib) with local treatments like ablation or radiation can help control early-stage non-small cell lung cancer in people who cannot have surgery or choose not to. About 45 participants with specific EGFR gene mutations will receive the combination therapy. The goal is to see if this approach improves survival and reduces cancer recurrence.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Shanghai Pulmonary Hospital
Shanghai, 200433, China
Conditions
Explore the condition pages connected to this study.